In recent years, immune checkpoint blockade (ICB) therapies, especially anti-programmed cell death (ligand) 1 (anti-PD-(L)1) and anti-cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4), have provided new hope for bladder cancer patients. Here, CD274 is linked to urinary bladder carcinoma.